Dr. McDermott on the Promise of Pembrolizumab in Non-Clear Cell RCC

Video

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non—clear cell renal cell carcinoma (RCC).

In findings from cohort B of the phase II KEYNOTE-427 study presented at the 2019 Genitourinary Cancers Symposium, pembrolizumab appeared to be safe. Only 6% of patients had to stop therapy due to a treatment-related adverse event. This is important because there are currently no FDA-approved therapies specifically for patients with non—clear cell RCC. The National Comprehensive Cancer Network guidelines recommend sunitinib (Sutent), but even the VEGF TKI is not indicated for this subgroup.

In fact, McDermott adds, prior immunotherapy trials in RCC have excluded patients with non—clear cell histology. The PD-1 inhibitor yielded a 24.8% response rate in the entire cohort of patients with non-clear cell RCC, giving researchers a reason to continue evaluating the drug’s benefit in this space.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Related Content
© 2025 MJH Life Sciences

All rights reserved.